QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NASDAQ:RETA

Reata Pharmaceuticals - RETA Price Target & Analyst Ratings

$49.23
-0.45 (-0.91%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$48.80
$50.00
50-Day Range
$33.91
$49.68
52-Week Range
$18.47
$50.99
Volume
709,808 shs
Average Volume
699,023 shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.67

Reata Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$66.67
35.42% Upside
High Prediction$115.00
Average Prediction$66.67
Low Prediction$40.00
TypeCurrent
2/7/22 to 2/7/23
1 Month Ago
1/8/22 to 1/8/23
3 Months Ago
11/9/21 to 11/9/22
1 Year Ago
2/7/21 to 2/7/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$66.67$66.67$63.13$85.00
Predicted Upside35.42% Upside85.01% Upside59.88% Upside38.13% Upside
Get Reata Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

RETA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RETA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reata Pharmaceuticals Stock vs. The Competition

TypeReata PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.64
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside35.42% Upside633.24% Upside8.48% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/28/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$86.00 ➝ $115.00+219.18%
11/15/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$40.00-4.01%
11/9/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$51.00 ➝ $53.00+31.55%
11/9/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$43.00 ➝ $50.00+24.10%
10/19/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$75.00+105.48%
5/11/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$75.00 ➝ $67.00+174.37%
12/9/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$282.00 ➝ $35.00-35.69%
12/7/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$230.00 ➝ $112.00+128.95%
11/25/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $234.00+58.54%
8/10/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$280.00 ➝ $225.00+115.93%
6/16/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$237.00+45.80%
4/17/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Maury Raycroft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$335.00 ➝ $348.00+135.28%
(Data available from 2/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RETA Price Target - Frequently Asked Questions

What is Reata Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Reata Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for RETA. The average twelve-month price prediction for Reata Pharmaceuticals is $66.67 with a high price target of $115.00 and a low price target of $40.00. Learn more on RETA's analyst rating history.

Do Wall Street analysts like Reata Pharmaceuticals more than its competitors?

Analysts like Reata Pharmaceuticals more than other Medical companies. The consensus rating for Reata Pharmaceuticals is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how RETA compares to other companies.

Does Reata Pharmaceuticals's stock price have much upside?

According to analysts, Reata Pharmaceuticals's stock has a predicted upside of 85.01% based on their 12-month price targets.

What analysts cover Reata Pharmaceuticals?

Reata Pharmaceuticals has been rated by Barclays, Citigroup, Robert W. Baird, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:RETA) was last updated on 2/7/2023 by MarketBeat.com Staff